Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer

Recruiting now

Conditions studied: Clinically Significant Prostate Cancer

In brief

The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.

Key facts

Study ID: NCT07492927
Run by: Xijing Hospital
People needed: 1700
Starts: 2021-03-12
Expected to finish: 2027-06-30
Last updated by the study team: 2026-03-25

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

Blood prostate-specific antigen PSA>4ng/dl;
Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging.
The patient is willing to undergo prostate biopsy.

You may not qualify if…

Previous diagnosis of prostate cancer through prostate biopsy;
History of other malignant tumors in the past two years;
According to the research physician''s judgment, serious complications may occur and affect the normal conduct of the experiment

Where it is running

Northwestern Memorial Hospital — Chicago, Illinois, United States (enrolling)
The First Hospital of Lanzhou University — Lanzhou, Gansu, China (enrolling)
General Hospital of Ningxia Medical University — Yinchuan, Ningxia, China (enrolling)
Qinghai University Affiliated Hospital — Xining, Qinghai, China (enrolling)
Weinan Central Hospital — Weinan, Shaanxi, China (enrolling)
Shaanxi Provincial People's Hospital — Xi'an, Shaanxi, China (enrolling)
Xijing 986 Hospital — Xi'an, Shaanxi, China (enrolling)
The Second Affiliated Hospital of Shaanxi University of Chinese Medicine — Xianyang, Shaanxi, China (enrolling)
Yan'an University Affiliated Hospital — Yan’an, Shaanxi, China (enrolling)
Xijing Hospital — Xi'an, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.